Coya Therapeutics, Inc. · NASDAQ:COYA
Coya Therapeutics — Investor Presentation (February 2026)
34 slides from Coya Therapeutics's investor presentation, February 2026
Slide 1: Addressing Neurodegeneration Via Treg Directed Combination Therapy
Addressing Neurodegeneration Via Treg Directed Combination Therapy Investor Overview February 2026
Slide 2: Cautionary Note of Forward-Looking Statements and Disclaimers
Cautionary Note of Forward-Looking Statements and Disclaimers in this Presentation This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-lo
Slide 3: Coya Therapeutics (COYA): Investment Highlights
Coya Therapeutics (COYA): Investment Highlights Indications With High Unmet Need • ALS, Frontotemporal Dementia (FTD), Alzheimer's Disease (AD) • De-risked approach with regulatory flexibility Novel Combination Therapies • COYA 302 (ALS, FTD) and COYA 303 (AD) have differentiated approach targeting
Slide 4: Key Catalysts and Milestones
Key Catalysts and Milestones COYA 302 in ALS: • Complete enrollment: expected 2H 2026 • Top-line data: expected 1Q 2027 ALSTARS (Phase 2) • Management to provide periodic updates COYA 302 in FTD: • Acceptance of IND: accepted 1Q 2026 • initiate Phase 2a study: expected 2H 2026 Translational Datasets
Slide 5: Pipeline > $10B Opportunity in ALS, FTD, AD & PD
Pipeline > $10B Opportunity in ALS, FTD, AD & PD COYA 302: ALS and FTD • High unmet need ALS FTD • Orphan indications • Flexible & fast path to market • > $5Bn market Neurodegeneraive Indications with High COYA 303: Alzheimer’s Unmet Medical Need Alzheimer’s Parkinson’s • One of most common Disease
Slide 6: LD IL-2 Combination Therapy: Pillars For Success
LD IL-2 Combination Therapy: 3 Pillars For Success The neurodegeneration field increasingly recognizes combination-based therapeutic strategies such as Coya's as a viable path forward for diseases driven by complex, multifactorial biology Differentiated Combination- Validated Science Early Clinical
Slide 7: Treg Focused Pipeline: Critical Role in Inflammation
Treg Focused Pipeline: Critical Role in Inflammation Tregs (Regulatory T Cells) By helping functional regulatory T cells (Tregs) maintain • Specialized immune cells that help immune balance, Coya combinations restrain chronic maintain a balanced immune system inflammation and limit pathways that dri
Slide 8: Treg Imbalance Leads to Neuroinflammation
Treg Imbalance Leads to Neuroinflammation… … And neuroinflammation leads to neurodegeneration, which drives disease progression Healthy Neuron Sick Neuron Dead Neuron Loss of selective population of neurons Healthy Tregs Pro-Inflammatory Cells
Slide 9: Rebalancing Treg Leads to Improved Clinical Outcomes
Rebalancing Treg Leads to Improved Clinical Outcomes Coya combination therapies: • Restore and enhance Tregs function, numbers, and survival • Mechanistically reduces chronic neuroinflammation due to immune dysregulation • Drive improved disease outcomes in neurodegenerative and autoimmune disease S
Slide 10: COYA 302 in ALS & FTD
COYA 302 in ALS & FTD Proprietary, Recombinant Human Low Dose Interleukin-2 (LD rhIL-2) and CTLA4-Ig
Slide 11: COYA 302 in ALS and FTD
COYA 302 in ALS and FTD ALS and Frontotemporal Dementia • High unmet need • Relatively short life expectancy from time of diagnosis • Significant loss of QoL • Orphan diseases • Flexible and fast paths to regulatory approval • ALS: ~33,000 patients in U.S. (NIH) • FTD: 50,000-60,000 patients in U.S.
Slide 12: COYA 302: Combo Therapies Enhance Treg Function
COYA 302: Combo Therapies Enhance Treg Function Dysfunctional immuno-regulatory environment due to inflammation Restoring Immune Regulation via Combination Therapy • Inflammation creates a dysfunctional immuno- regulatory environment o Tregs are dysregulated and dysfunctional Dysfunctional Tregs CD8
Slide 13: COYA 302 in ALS
COYA 302 in ALS
Slide 14: Current ALS Therapies aim to slow disease progression
Current ALS Therapies aim to slow disease progression Many companies have garnered significant value by demonstrating a limited benefit of slowing the rate of ALS progression 2 3 Baseline 4 8 12 16 20 24 Weeks ALS patients average rate of decline is ~1 point/month in ALSFRS-R score1 1. The PRO-ACT d
Slide 15: LD IL-2 + CTLA4-Ig: Signal in Mild-to-Moderate ALS
LD IL-2 + CTLA4-Ig: Signal in Mild-to-Moderate ALS • Investigator Initiated Trial • 4 mild-to-moderate ALS patients • Low-dose IL-2 + CTLA4 Ig led to stable or improved ALSFRS-R Scores • Ameliorate ALS progression over 48 weeks • Well tolerated over 48 weeks (the most common AE mild was ISR) Partici
Slide 16: LD IL-2+CTLA4 Ig: Restored Treg Suppressive Function
LD IL-2+CTLA4 Ig: Restored Treg Suppressive Function LD IL-2 + CTLA4 Ig combination is synergistic and effective ** ** ** * LD IL-2 + CTLA4-Ig * • Significantly expanded Treg suppressive function as early as week 4 ** • Maintained a significantly increased Treg function • Increased Treg numbers as e
Slide 17: COYA 302: Initiated ALSTARS Phase 2 Study in ALS
COYA 302: Initiated ALSTARS Phase 2 Study in ALS Key Inclusion Criteria Primary Endpoint Randomized, Double-Blind, Placebo-Controlled Change in disease • Diagnosis of sporadic or Phase 2 Study with Blinded Active Extension severity over time familial ALS measured by ALSFRS-R • ALSFR-R score ≥ 35 at
Slide 18: COYA 302 in FTD
COYA 302 in FTD
Slide 19: LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD
LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD Encouraging clinical data in FTD in Investigator Sponsored Study • Treg suppressive function and percentage: o Increased after first treatment o Remained elevated across 22-week treatment period Increased Treg Suppressive Function Expansion of Treg
Slide 20: LD IL-2 & CTLA-4 Ig: Signal in FTD – cont.
LD IL-2 & CTLA-4 Ig: Signal in FTD – cont. Cognitive Stability in 22-Week Investigator Sponsored Study • CDR-FTLD, MoCA, PASS cognitive tests exhibited no cognitive decline at end of study compared with baseline Moca Scores Remains CDR-FTLD Scores Remains Unchanged Compared to Unchanged Compared to
Slide 21: COYA-302 in FTD: Phase 2a Expected 2Q 2026 Start
COYA-302 in FTD: Phase 2a Expected 2Q 2026 Start Primary Endpoint Randomized, Double-Blind, Placebo-Controlled • Safety and Phase 2a Study with Open Label Extension tolerability Key Inclusion Criteria 4 wk. 24 wk. Double Blind 24 week Open Label Clinical Efficacy • Non-Fluent Primary Screening Treat
Slide 22: COYA 301
COYA 301 Proprietary Low Dose Recombinant Human IL-2
Slide 23: LD IL-2 Monotherapy in AD: Exciting Phase I POC
LD IL-2 Monotherapy in AD: Exciting Phase I POC LD IL-2 monotherapy works in Alzheimer's • Enhanced Treg function and numbers • Stabilized cognitive decline Combination with GLP-1 receptor agonist offers: • Enhanced clinical benefit • Synergistic advantage over monotherapy • Validation of low-dose I
Slide 24: COYA 303 in Alzheimer's
COYA 303 in Alzheimer's Proprietary, Recombinant Human Low Dose Interleukin-2 (LD rhIL-2) and GLP-1 RA
Slide 25: COYA in Alzheimer's Disease
COYA 303 in Alzheimer's Disease Alzheimer's Disease • High unmet need • Significant loss in QoL • >7 million patients in U.S. COYA 303 • Proprietary combination (co-administered) • Recombinant Human Low Dose Interleukin-2 (LD rhIL-2) and GLP-1 receptor agonist • IP through 2040's Strong scientific r
Slide 26: COYA in Alzheimer's: Compelling Preclinical Signal
COYA 303 in Alzheimer's: Compelling Preclinical Signal Encouraging in-vitro and in LPS mouse model • Lipopolysaccharide (LPS) mouse model is well-characterized of systemic and neuro-inflammation • COYA 303 decreased both periphery inflammation and in neuro-inflammation • Mechanistic synergy: complem
Slide 27: Leadership
Leadership • Management • Scientific Advisory Board • Board of Directors
Slide 28: Management
Management Arun Swaminathan, Fred Grossman, D.O., David Snyder Ph.D. FAPA Chief Financial Officer & Chief Executive Officer President & Chief Chief Operating Officer Medical Officer • Bristol Myers Squibb • Johnson-Johnson • DisperSol Technologies • Actinium • Sunovion • Exicure • Covance • Bristol
Slide 29: Experienced Development Team
Experienced Development Team Michelle Frazier, Ph.D. Karen King, MS Daniel Barvin, M.B.A Senior Vice President of Management and Clinical Vice President of Regulatory Affairs Operations Operations & Patient Advocacy • Revance Therapeutics • Recursion • End The Legacy: • CytomX • MacroGenics Genetic
Slide 30: Scientific Advisors Board
Scientific Advisors Board Shimon Sakaguchi, Clive Svendsen, Ph.D. Malcolm Brenner, M.D., Stanley Appel, M.D. M.D., Ph.D. Director, Cedars-Sinai Ph.D. Co-Director, Houston Member of the National Regenerative Medicine Director, Center for Cell and Methodist Neurological Institute Gene Therapy Institut
Slide 31: Board of Directors
Board of Directors Howard Berman, Ph.D. Ann Lee, Ph.D. Dov Goldstein, M.D., MBA Executive Chairman Chief Technical Officer Chief Financial Officer of the Board Prime Medicine BioAge Labs Wilbur Ross Anabella Villalobos, Ph.D. Dieter Weinand Former U.S. Secretary of Former Head of Biotherapeutics For
Slide 32: Appendix
COYA THERAPEUTICS Appendix
Slide 33: LD IL-2 + CTLA4-Ig Investigator Initiated Clinical Trial
LD IL-2 + CTLA4-Ig Investigator Initiated Clinical Trial Open-Label, Single-Arm PoC Clinical Study in ALS Patients (N=4) Screening Treatment Period Follow-Up 20 weeks LD IL-2 + CTLA4-Ig was administered via 8 weeks subcutaneous injection over 48 weeks Screening Assessments Treatment Period Assessmen
Slide 34: LD IL-2 + CTLA4-Ig Investigator Initiated Clinical Trial: Baseline Characteristics
LD IL-2 + CTLA4-Ig Investigator Initiated Clinical Trial Baseline Characteristics ALS Progression Age Respiratory Respiratory Sex Type Onset Prior to Baseline (years) Status Support (ALSFRS-R score) No Respiratory Patient 1 47 Female Familial Limb -1.6 points / month None Insufficiency Respiratory N
Coya Therapeutics — Investor Presentation (February 2026) on 6ix